Figure 1.
Comparison of the respective mutational spectrum detected by targeted sequencing of both archived FFPE tumor tissue material, taken at time-point of first diagnosis, and ctDNA, isolated from blood plasma at baseline, prior to initiation of the respective therapy line, for (A) therapy naïve patients and (B) pretreated patients.